EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

Bayer

Status: Completed

Conditions: Hypertension, Pulmonary

Treatments: Drug: Riociguat (Adempas, BAY63-2521)

Study type: Observational

Funder types: Industry

Identifiers

NCT02092818

AD1301 (Other Identifier)

16657

Details and patient eligibility

About

In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.

Enrollment: 1,316 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and male patients who start or are on treatment with Adempas
• Written informed consent

Exclusion criteria

• Patients currently participating in an interventional clinical trial

Trial design

1,316 participants in 1 patient group

Group 1

Description:

Patients who have been prescribed Adempas for a medically appropriate use

Treatment:

Drug: Riociguat (Adempas, BAY63-2521)